Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Observer-Blind, Randomized, Parallel Groups, Single-Center, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of Two 0.25 mL Intramuscular Doses of Three Commercially Available Influenza Vaccines in Healthy Subjects Aged 6 to <36 Months.

NCT00311428 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00311428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00311428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Observer-Blind, Randomized, Parallel Groups, Single-Center, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of Two 0.25 mL Intramuscular Doses of Three Commercially Available Influenza Vaccines in Healthy Subjects Aged 6 to <36 Months.
Lead sponsor
Novartis
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2005
Completion date
Not reported
Enrollment
270
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza